TXG
10X Genomics Inc
84.10$
+11.2%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 37.8% | 37.1% | 34.1% | 31.9% | 29.8% | 32.8% | 31.9% | 27.7% | 32.7% | 31.9% | 29.6% | 25.5% | 30.0% | |
| 62.2% | 62.9% | 65.9% | 68.1% | 70.2% | 67.2% | 68.1% | 72.3% | 67.3% | 68.1% | 70.4% | 74.5% | 70.0% | |
| 70.2% | 35.5% | 48.7% | 41.1% | 43.6% | 40.6% | 41.5% | 35.4% | 38.4% | 33.7% | 37.7% | 37.6% | 36.8% | |
| 53.6% | 45.0% | 60.8% | 54.2% | 53.9% | 54.5% | 57.9% | 43.0% | 50.6% | 46.1% | 44.0% | 52.1% | 48.1% | |
| 123.9% | 92.9% | 109.5% | 95.3% | 97.5% | 97.4% | 93.5% | 54.9% | 89.0% | 79.9% | 81.7% | 87.4% | 84.4% | |
| -61.7% | -30.0% | -43.6% | -27.3% | -27.4% | -30.2% | -25.4% | 17.4% | -21.6% | -11.8% | -11.3% | -12.9% | -14.3% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | 0.0% | – | |
| -59.7% | -25.3% | -41.0% | -24.2% | -22.7% | -29.3% | -21.6% | 21.4% | -18.9% | -9.2% | -8.5% | -12.3% | -12.1% | |
| 0.8% | 1.3% | 1.5% | 0.5% | 0.9% | 0.4% | 0.6% | 1.4% | -0.5% | 0.6% | 0.4% | -0.5% | 0.0% | |
| -60.5% | -26.6% | -42.5% | -24.8% | -23.6% | -29.7% | -22.2% | 20.0% | -18.4% | -9.8% | -8.9% | -11.9% | -12.2% | |
| -52.3% | -19.0% | -32.8% | -17.1% | -15.6% | -22.9% | -15.3% | 27.0% | -10.7% | 38.3% | -0.6% | -12.3% | 4.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.